Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Rivista Di Psichiatria|October 22, 2015
Drug interactions with vortioxetine, a new multimodal antidepressantEdoardo Spina, Vincenza SantoroClinical Therapeutics|August 12, 2008
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an updateEdoardo Spina, Vincenza Santoro, Concetta D'ArrigoTherapeutic Drug Monitoring|June 17, 2006
Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionConcetta D'Arrigo, Gaetana Migliardi, Vincenza Santoro, et al.Expert Opinion on Drug Metabolism & Toxicology|February 16, 2012
Interactions between antiepileptics and second-generation antipsychoticsJose de Leon, Vincenza Santoro, Concetta D'Arrigo, et al.Pharmacological Research|October 18, 2005
Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophreniaConcetta D'Arrigo, Gaetana Migliardi, Vincenza Santoro, et al.Therapeutic Drug Monitoring|April 2, 2015
Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After SwitchingDomenico Italiano, Antonio Bruno, Vincenza Santoro, et al.Journal of Biopharmaceutical Statistics|March 16, 2012
Drug dosage individualization based on a random-effects linear modelFrancisco J Diaz, Myladis R Cogollo, Edoardo Spina, et al.Clinical Neuropharmacology|April 7, 2007
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disordersGaetana Migliardi, Concetta D'Arrigo, Vincenza Santoro, et al.Drugs - Real World Outcomes|September 16, 2021
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance DatabaseMaria Antonietta Barbieri, Emanuela Elisa Sorbara, Giuseppe Cicala, et al.Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting SystemGiuseppe Cicala, Giulia Russo, Vincenza Santoro, et al.Pageof 3